In this latest issue of The Scientist, portfolio company Lucid Scientific's Recipher Platform is highlighted by researchers at Memorial Sloan Kettering Cancer Center as a novel way to measure live oxygen consumption rate (OCR) in cell culture. OCR, and more specifically the amount of oxygen available at the cells is a critical parameter Lucid's technology provides.